Joe Tr Clarke

List of Publications by Year
in descending order

25 papers	1,524 citations	430874 18 h-index	677142 22 g-index
27 all docs	27 docs citations	27 times ranked	1824 citing authors

#	Article	IF	Citations
1	Narrative Review: Fabry Disease. Annals of Internal Medicine, 2007, 146, 425.	3.9	177
2	The Natural History of Juvenile or Subacute GM2 Gangliosidosis: 21 New Cases and Literature Review of 134 Previously Reported. Pediatrics, 2006, 118, e1550-e1562.	2.1	165
3	Mutation analysis ofPEX7 in 60 probands with rhizomelic chondrodysplasia punctata and functional correlations of genotype with phenotype. Human Mutation, 2002, 20, 284-297.	2.5	122
4	Early treatment of Menkes disease with parenteral Cooper-Histidine: Long-term follow-up of four treated patients. , 1998, 76, 154-164.		109
5	An overview of L-2-hydroxyglutarate dehydrogenase gene (L2HGDH) variants: a genotype-phenotype study. Human Mutation, 2010, 31, 380-390.	2.5	108
6	Efficient analysis of urinary glycosaminoglycans by LC-MS/MS in mucopolysaccharidoses type I, II and VI. Molecular Genetics and Metabolism, 2011, 102, 49-56.	1.1	96
7	Early copper-histidine treatment for Menkes disease. Nature Genetics, 1996, 12, 11-13.	21.4	94
8	How well does urinary lyso-Gb3 function as a biomarker in Fabry disease?. Clinica Chimica Acta, 2010, 411, 1906-1914.	1.1	94
9	Urinary globotriaosylceramide excretion correlates with the genotype in children and adults with Fabry disease. Molecular Genetics and Metabolism, 2008, 93, 331-340.	1.1	88
10	An improved method for glycosaminoglycan analysis by LCâ€“MS/MS of urine samples collected on filter paper. Clinica Chimica Acta, 2012, 413, 771-778.	1.1	62
11	Urinary biomarker investigation in children with Fabry disease using tandem mass spectrometry. Clinica Chimica Acta, 2015, 438, 195-204.	1.1	62
12	UPLC-MS/MS detection of disaccharides derived from glycosaminoglycans as biomarkers of mucopolysaccharidoses. Analytica Chimica Acta, 2016, 936, 139-148.	5.4	53
13	Late onset Leigh syndrome and ataxia due to a T to C mutation at bp 9,185 of mitochondrial DNA. American Journal of Medical Genetics, Part A, 2007, 143A, 808-816.	1.2	51
14	Novel mutations in dihydrolipoamide dehydrogenase deficiency in two cousins with borderline-normal PDH complex activity. American Journal of Medical Genetics, Part A, 2006, 140A, 1542-1552.	1.2	48
15	Clinical and genetic aspects of trigonocephaly: A study of 25 cases. , 2002, 117A, 127-135.		41
16	Systolic Myocardial Mechanics in Patients with Andersonâ€“Fabry Disease with and without Left Ventricular Hypertrophy and in Comparison to Nonobstructive Hypertrophic Cardiomyopathy. Echocardiography, 2012, 29, 810-817.	0.9	39
17	Organic Acidurias and Related Abnormalities. Critical Reviews in Clinical Laboratory Sciences, 1995, 32, 377-429.	6.1	29
18	A Survey of the Pain Experienced by Males and Females with Fabry Disease. Pain Research and Management, 2006, 11, 185-192.	1.8	21

#	Article	IF	Citations
19	Changes in plasma and urine globotriaosylceramide levels do not predict Fabry disease progression over 1 year of agalsidase alfa. Genetics in Medicine, 2013, 15, 983-989.	2.4	21
20	The use of agalsidase alfa enzyme replacement therapy in the treatment of Fabry disease. Expert Opinion on Biological Therapy, 2009, 9, 631-639.	3.1	18
21	Interstitial deletion of 1p22.2p31.1 and medium-chain acyl-CoA dehydrogenase deficiency in a patient with global developmental delay. American Journal of Medical Genetics, Part A, 2008, 146A, 1581-1586.	1.2	11
22	Left Ventricular Aneurysm Associated With Mucopolysaccharidosis Type VI Syndrome (Maroteauxâ€“Lamy Syndrome). Circulation, 2007, 115, e60-2.	1.6	8
23	Managing sickle cell carrier results generated through newborn screening in Ontario: a precedent-setting policy story. Genetics in Medicine, 2017, 19, 625-627.	2.4	5
24	Agalsidase alfa therapy for Fabry disease. Expert Review of Endocrinology and Metabolism, 2007, 2, 147-154.	2.4	1
25	Congratulations on passing your specialty examinations. Paediatrics and Child Health, 2010, 15, 137-138.	0.6	0